VASCULAR FLOW TECHNOLOGIES LIMITED

Their core work

Vascular Flow Technologies is a Dundee-based medical device SME that develops engineered implants targeting blood flow dynamics and vascular repair. Their flagship work is the SpiraStent, an endovascular stent designed to induce spiral laminar flow and reduce restenosis in peripheral arterial disease — a problem that plagues conventional stent designs. More recently, they have joined the bioresorbable materials space, contributing industrial and clinical perspective to research on polymers, composites, and textile-based scaffolds that dissolve after healing is complete. Their value lies at the intersection of device engineering and materials science: they understand both how blood flows through implants and what those implants are made of.

What they specialise in

How they've shifted over time

VFT's early H2020 activity (2014–2015) centred entirely on proprietary stent engineering — specifically the spiral laminar flow concept applied to peripheral arterial disease, with no publicly tagged keyword data beyond the project title itself. By their second project (2019–2023), the focus had broadened markedly: the keyword set is dominated by materials science terms — bioresorbable, biodegradable, polymers, composites, textiles — reflecting a pivot from device geometry to device composition. The likely explanation is that SpiraStent demonstrated the clinical need for better implant materials, and VFT followed that thread into the bioresorbable space as an industry partner in a training consortium.

VFT appears to be building toward a next-generation resorbable vascular stent — combining their proprietary flow-engineering know-how with the bioresorbable polymer and composite expertise gained through BioImplant ITN.

How they like to work

VFT has operated in both roles: as a coordinator driving their own innovation (SpiraStent, SME Phase 1) and as an industry participant enriching an academic training network (BioImplant ITN, MSCA-ITN). Their total consortium footprint is compact — 8 partners across 4 countries — suggesting they work in focused, high-trust teams rather than large open consortia. As an SME, they typically bring clinical insight, device prototyping capability, and commercialisation pathways that academic-led consortia need to satisfy EU impact requirements.

VFT has collaborated with 8 unique partners across 4 countries over two projects, indicating a compact but genuinely international network. The geographic spread suggests European academic and research partners rather than purely UK-based ties.

What sets them apart

VFT is unusual among medical device SMEs in holding both a proprietary biomechanical concept (spiral laminar flow induction) and a materials science research track — most device companies specialise in one or the other. Their SME Phase 1 coordinator history signals that they can originate and lead projects, not just follow larger partners. For a consortium building a vascular or resorbable implant project, they bring a credible combination of clinical problem-ownership, device design background, and industrial translation capacity that few SMEs at this scale can offer.

Highlights from their portfolio

• SpiraStent
  VFT coordinated this SME Phase 1 project, making it the clearest evidence of their proprietary technology — a stent designed around spiral laminar flow physics to improve outcomes in peripheral arterial disease.
• BioImplant ITN
  Participation in this MSCA training network (2019–2023) shows VFT's strategic move into bioresorbable materials, connecting them to a multi-country academic consortium and a new generation of researchers in the field.